Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma
- 1 February 2004
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 2-6
- https://doi.org/10.1053/j.seminoncol.2003.12.002
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)Blood, 2003
- Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphomaSeminars in Oncology, 2003
- The mechanisms of action of rituximab in the elimination of tumor cellsSeminars in Oncology, 2003
- RituximabDrugs, 2003
- Mantle-cell lymphomaThe Lancet Oncology, 2001
- Autologous hematopoietic stem cell transplantation for mantle cell lymphomaTransplantation and Cellular Therapy, 2000
- European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic LymphomaJournal of Clinical Oncology, 2000
- Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.Journal of Clinical Oncology, 1998
- High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.Journal of Clinical Oncology, 1998
- High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patientsBone Marrow Transplantation, 1998